# US 7,744,880 B2 · Cell growth inhibitors containing anti-glypican 3 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,880 B2
- Document ID: US7744880B2
- Status: Granted
- Kind: B2
- Application number: 11/702,780
- Filed: 2007-02-05
- Published: 2007-07-26
- Granted: 2010-06-29
- Earliest claimed: 2001-06-22
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Hiroyuki Aburatani; Tetsuo Nakamura; Masayuki Tsuchiya
- Web page: https://patentgrep.com/patent/US7744880B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/3076: {against structure-related tumour-associated moieties}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.

## Claims

### Claim 1

A method of treating hepatic cancer comprising administering to a patient in need thereof a pharmaceutical composition containing an anti-glypican 3 antibody as an active ingredient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-glypican 3 antibody has cytotoxic activity.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cytotoxic activity is antibody-dependent cell-mediated cytotoxicity (ADCC) activity or complement-dependent cytotoxicity (CDC) activity.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-glypican 3 antibody is a human antibody, humanized antibody or a chimeric antibody.